On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83.
This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history reveals that the best stocks typically have an 80 or higher RS Rating as they begin their biggest runs.
Risk Management In The Stock Market: How Much Money To Invest Now
Is Guardant Health Stock A Buy?
Guardant Health stock is trying to complete a cup without handle with a 37.04 entry. See if the medical stock can break out in heavy volume. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
The precision oncology company showed 0% EPS growth in the latest quarterly report, while sales growth came in at 34%.
Guardant Health stock holds the No. 9 rank among its peers in the Medical-Services industry group. Hims & Hers Health, Castle Biosciences and Quest Diagnostics are among the top 5 highly rated stocks within the group.
